Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Palbociclib

3 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

ECOGTHOS1400

04/02/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Treatment

VICCURO1473

01/09/2015

A Randomized Phase II Study of Androgen Deprivation Therapy with or without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer.

Treatment

VICCMELP1388

03/24/2014

A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors.